<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04122547</url>
  </required_header>
  <id_info>
    <org_study_id>25132558</org_study_id>
    <nct_id>NCT04122547</nct_id>
  </id_info>
  <brief_title>Efficacy of Roflumilast on Exacerbations in Patients With Non-cystic Fibrosis Bronchiectasis</brief_title>
  <official_title>Efficacy of Roflumilast on Exacerbations in Patients With Non-cystic Fibrosis Bronchiectasis: a Randomized Double-blind Placebo-controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prince of Songkla University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Prince of Songkla University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Roflumilast compare with placebo for decrease infected exacerbation in non-cystic
      Bronchiectasis
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Efficacy and RCT compare roflumilast vs placebo for 6 months in frequent infectious
      exacerbation in non-cystic bronchiectasis in Thailand
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>acute deterioration of of bronchiectasis symptoms</measure>
    <time_frame>6 months</time_frame>
    <description>acute dyspnea worsening respiratory of symptoms</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lung functions</measure>
    <time_frame>6 months</time_frame>
    <description>FEV1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exercise capacity</measure>
    <time_frame>6 months</time_frame>
    <description>6 minute walk distance</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Health related Quality of life</measure>
    <time_frame>6 months</time_frame>
    <description>SGRQ scores, score range from 0-80, high score mean more symptoms</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Exacerbation Copd</condition>
  <condition>Bronchiectasis</condition>
  <condition>Lung Function Decreased</condition>
  <arm_group>
    <arm_group_label>Roflumilast</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Roflumilast 500 microgram one tab oral per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>One tablet oral per day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Roflumilast</intervention_name>
    <description>Active drug</description>
    <arm_group_label>Roflumilast</arm_group_label>
    <other_name>Daxas</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo one tablet oral od</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  symptomatic Bronchiectasis

          -  history at least 2 exacerbation last year

        Exclusion Criteria:

          -  comorbidity with chronic obstructive pulmonary disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kanung Saejiam, MS</last_name>
    <role>Study Director</role>
    <affiliation>Prince of Songkla University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Songklanagarind hospital</name>
      <address>
        <city>Songkhla</city>
        <zip>90110</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 8, 2019</study_first_submitted>
  <study_first_submitted_qc>October 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 10, 2019</study_first_posted>
  <last_update_submitted>October 9, 2019</last_update_submitted>
  <last_update_submitted_qc>October 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Prince of Songkla University</investigator_affiliation>
    <investigator_full_name>Siwasak Juthong</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>Bronchiectasis</keyword>
  <keyword>roflumilast</keyword>
  <keyword>exacerbation</keyword>
  <keyword>lung function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bronchiectasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

